DOCSLIB.ORG

March 2, 2016 Martha Kruhm, MS RAC Head, Protocol And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
March 2, 2016 Martha Kruhm, MS RAC Head, Protocol And Operations Office – Boston March 2, 2016 Martha Kruhm, MS RAC Head, Protocol and Information Office Quality Assurance Section CTEP, DCT, NCI 6130 Executive Blvd, EPN Room 7000 Bethesda, MD 20892 Dear Ms. Kruhm: Enclosed is Addendum #5 to E3611, A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination with High Dose Interferon-α in Advanced Melanoma. This amendment is in response to Drs. Howard Streicher, James Zwiebel, and Meg Mooney’s Request for Rapid Amendment on March 1, 2016. The following revisions to E3611 protocol have been made in this addendum: Section Change 1. Cover page Updated version date 2. Section 5.3 Replaced ipilimumab CAEPR with updated Version 2.7, June 28, 2015 The following revisions to E3611 Informed Consent Document have been made in this addendum: Section Change 1. Cover page Updated version date 2. “Non immune-based Removed instructional text titled “Please note the following in reviewing Risks Associated these risks” and replaced condensed risk list with updated Version 2.7, with Ipilimumab” June 28, 2015 If you have any questions regarding this addendum, please contact [email protected] or 617-632-3610. We request review and approval of this addendum to E3611 so ECOG-ACRIN may activate it promptly. Thank you. i 900 Commonwealth Avenue, Boston, MA 02215 p: 617.632.3610 f: 617.632.2990 ecog-acrin.org Sincerely, Pamela Cogliano Protocol Development Manager Enclosure CC: Ahmad Tarhini, MD, PhD Carol Chami, R.N. Sandra Lee, ScD Melinda Flood Uma Rao, MD Bruce Giantonio, M.D. Robert L. Comis, M.D John Kirkwood, MD Kerry Higgins Ross Goldberg Mary Steele Sarah Archambault Jean MacDonald Donna Marinucci James Corkery Lauren Lambert Amy Li Lam Le ii E3611 A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination with High Dose Interferon-α in Advanced Melanoma STUDY CHAIR: Ahmad A. Tarhini MD, PhD STUDY CO-CHAIR: John M Kirkwood, MD STUDY STATISTICIAN: Sandra Lee, ScD PATHOLOGY CO-CHAIR: Uma Rao, MD MELANOMA COMMITTEE CHAIR: John M Kirkwood, MD Version Date: March 2, 2016 STUDY PARTICIPANTS ACTIVATION DATE US Sites Only December 27, 2012 Addendum #1 – Incorporated prior to activation Addendum #2 – 5/14 Addendum #3 - 10/14 Addendum #4 - 4/15 Addendum #5 – 3/16 Agents IND# NSC# Supply Ipilimumab 10200 732442 NCI Supplied Interferon 377523 Commercial 1 ECOG-ACRIN E3611 Cancer Research Group Version Date: March 2, 2016 Table of Contents Schema ...................................................................................................................... 6 1. Introduction ........................................................................................................ 7 1.1 Management of Metastatic Melanoma and the Role of CTLA4 Blockade 7 1.2 IFN-2b and the Role of High-Dose IFN-α2b (HDI) as Adjuvant Therapy for High-risk Resected Melanoma ............................................................. 8 1.3 CTLA-4 and T Cell Activation ..................................................................... 9 1.4 Summary of Results of Investigational Program of Ipilimumab ............. 10 1.5 Overall Risk/Benefit Assessment of Ipilimumab Studies ........................ 27 1.6 A phase II study of tremelimumab combined with HDI for metastatic melanoma ............................................................................................... 28 1.7 Study Rationale ....................................................................................... 34 2. Objectives ......................................................................................................... 37 2.1 Primary Endpoints ................................................................................... 37 2.2 Secondary Endpoints............................................................................... 37 3. Selection of Patients ......................................................................................... 38 3.1 Eligibility Criteria ..................................................................................... 38 4. Registration Procedures.................................................................................... 42 4.1 Protocol Number ..................................................................................... 44 4.2 Investigator Identification ....................................................................... 44 4.3 Patient Identification .............................................................................. 44 4.4 Eligibility Verification .............................................................................. 44 4.5 Stratification Factors ............................................................................... 44 4.6 Additional Requirements ........................................................................ 44 4.7 Instructions for Patients who Do Not Start Assigned Protocol Treatment45 5. Treatment Plan ................................................................................................. 46 5.1 Administration Schedule ......................................................................... 46 5.2 Adverse Event Reporting Requirements ................................................. 48 5.3 Comprehensive Adverse Events and Potential Risks List ........................ 56 5.4 Dose Modifications ................................................................................. 60 5.5 Supportive Care and Prohibited Therapies ............................................. 80 5.6 Duration of Therapy ................................................................................ 81 5.7 Duration of Follow-up ............................................................................. 81 6. Measurement of Effect ..................................................................................... 82 6.1 Antitumor Effect – RECIST ....................................................................... 82 6.2 Definition of Tumor Response Using irRC ............................................... 90 7. Study Parameters .............................................................................................. 93 7.1 Therapeutic Parameters.......................................................................... 93 7.2 Arms A and C: Patients Treated with HDI and Ipilimumab at 10 mg/kg (Arm A) or 3 mg/kg (Arm C) .................................................................... 94 7.3 Arms B and D: Patients Treated with Ipilimumab alone at 10 mg/kg (Arm B) or 3 mg/kg (Arm D) ............................................................................. 97 2 ECOG-ACRIN E3611 Cancer Research Group Version Date: March 2, 2016 7.4 Biological Sample Submissions ............................................................. 100 8. Drug Formulation and Procurement ............................................................... 101 8.1 Ipilimumab ............................................................................................ 101 8.2 Alfa Interferon ....................................................................................... 105 9. Statistical Considerations ................................................................................ 110 9.1 Endpoints and Sample Size ................................................................... 110 9.2 Stratification .......................................................................................... 111 9.3 Gender and Ethnicity ............................................................................ 112 10. Pathology Review ............................................................................................ 113 10.1 Pathology Materials Required For This Protocol .................................. 113 10.2 Shipping Procedures ............................................................................. 114 10.3 ECOG-ACRIN Sample Tracking System .................................................. 115 11. Submission of Samples ................................................................................... 116 11.1 Sample Submission Schedule ................................................................ 116 11.2 Sample Preparation Guidelines ............................................................. 116 11.3 Shipping Kits .......................................................................................... 117 11.4 Shipping Procedures ............................................................................. 117 11.5 Use of Specimens in Research .............................................................. 118 11.6 Sample Inventory Submission Guidelines ............................................. 118 12. Electronic Data Capture .................................................................................. 119 12.1 Records Retention ................................................................................. 119 3 ECOG-ACRIN E3611 Cancer Research Group Version Date: March 2, 2016 13. Patient Consent and Peer Judgment .............................................................. 120 14. References ...................................................................................................... 120 Appendix I Pathology Submission Guidelines ...................................................... 125 Appendix II Patient Thank You Letter ................................................................... 131 Appendix III Patient Interferon Diary ................................................................... 132 Appendix IV E3611 Cooperative Research and Development
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • A Phase Ib Study Evaluating Cobimetinib Plus
    Official Title: A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma NCT Number: NCT03178851 Document Date: Protocol Version 5: 26-October-2018 PROTOCOL TITLE: A PHASE IB STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH V600 ADVANCED BRAF WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI−PD-1 THERAPY AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED V600 BRAF WILD-TYPE MELANOMA PROTOCOL NUMBER: CO39721 VERSION NUMBER: 5 EUDRACT NUMBER: 2016-004402-34 IND NUMBER: 135,717 TEST PRODUCTS: Cobimetinib (RO5514041) Atezolizumab (RO5541267) MEDICAL MONITOR: M.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: 14 December 2016 DATES AMENDED: Version 2: 23 June 2017 Version 3: 19 September 2017 Version 4: 3 February 2018 Version 5: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 26-Oct-2018 10:19:14 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board.
    [Show full text]
  • A Potential Emergency Department Diagnostic Pitfall
    1970 Correspondence / American Journal of Emergency Medicine 37 (2019) 1963–1988 [8] Kelen GD et al. Hepatitis B and hepatitis C in emergency department patients - formed by a laboratory technician, and each hematology lab PubMed - NCBI, 2019. defines specified criteria to trigger performance of a manual differ- [9] Federman A. An electronic health record-based intervention to promote ential. Hospital-based labs commonly perform manual differen- hepatitis C virus testing among adults born between 1945 and 1965: a cluster- randomized trial, 55, 2018. p. 1. tials when flagged cells are reported on automated counts, or [10] Bragg DA, Crowl A, Manlove E. Hepatitis C. A New Era Prim Care when samples are submitted from specified departments (e.g. 2017;44:631–42. Emergency Departments). However, the process of identifying and quantifying ‘‘bandemia” is time-consuming, and results may become available much later than initial CBC results. Further, clin- ‘‘Bandemia” without leukocytosis: A potential icians may be unaware of flagged results as manual differentials Emergency Department diagnostic pitfall are queued and pending if no reporting system for flagged auto- mated results exists. Emergency physicians must recognize this complex and variable reporting process to avoid early discharge Emergency physicians routinely employ leukocyte counts as a of otherwise well-appearing patients before determination of band risk stratification tool in a variety of clinical presentations. While counts. a leukocyte count within the normal reference range is widely Emergency physicians face increasing external forces to acknowledged as unreliable, it is nonetheless commonly inter- improve both efficiency and accuracy while operating in an inher- preted as reassuring in a patient not otherwise suspected of har- ently high-stakes clinical setting.
    [Show full text]
  • White Blood Cell Left Shift in a Neonate: a Case of Mistaken Identity
    Journal of Perinatology (2006) 26, 378–380 r 2006 Nature Publishing Group All rights reserved. 0743-8346/06 $30 www.nature.com/jp PERINATAL/NEONATAL CASE PRESENTATION White blood cell left shift in a neonate: a case of mistaken identity ISI Mohamed, RJ Wynn, K Cominsky, AM Reynolds, RM Ryan, VH Kumar and S Lakshminrusimha Department of Pediatrics, Division of Neonatology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Women and Children’s Hospital of Buffalo, Buffalo NY, USA Case report We present a full-term male infant who presented with tachypnea and an A male infant was delivered to a 36-year-old, G P , Caucasian increased band count on his complete blood count (CBC) with an 4 3003 mother. Maternal blood type was A negative, and she had received immature to total neutrophil (I:T) ratio of 0.6 raising suspicion of early Rhogam. Serology testing was unremarkable (rubella immune, onset sepsis. A blood culture was drawn and he was started on appropriate VDRL nonreactive, hepatitis B surface antigen and HIV negative) antibiotics. The patient’s clinical condition rapidly improved; however, the and third trimester group B streptococcal culture was negative. white cell count ‘left shift’ persisted. When a detailed family history was Maternal medical history, past history, family history and social obtained, it was discovered that the father, paternal uncle and the history were all negative. Membranes ruptured 5 ½ h before grandfather had been diagnosed with Pelger-Huet anomaly (PHA). As the delivery with clear amniotic fluid. There were no signs or urine, blood and CSF cultures were all negative in this now well-appearing symptoms of chorioamnionitis.
    [Show full text]
  • Physician Education in Clinical Documentation Improvement
    Physician Education in Clinical Documentation Improvement: Accurately Documenting and Supporting Diagnoses in the Delivery of Medically Necessary and Appropriate Healthcare Marianne Ries, MD, MBA, CPE Revenue Cycle and Institute for Population Health Lost in Middle America 3 The Best… 3 The Worse… 3 Oh, And We Have Weather TOO… 3 Identification of Problematic Physician Documentation 1. Internal source THR-specific 2. PEPPER 3. National Data 4. Targeted Audits 5. Denials 3 High Risk Physician Documentation 1. Cut and paste 2. Carry forward 3. Voice-to-text and dictation 4. Observation services indications 5. Short stay inpatient admissions 3 Documentation Connection Between Diagnoses and Medical Necessity • Supports that services are reasonable and medically necessary to the diagnosis made and/or treatment of that medical condition • Shows evaluating, diagnosing, or treating an illness, injury, or disease, is in accordance with accepted standards • Diagnosis reported supports the medical necessity of services 3 Valid Diagnoses: Foundation of Medical Necessity for Hospitalization - The Bread and Pasta of Medically Necessary Services 3 Valid Diagnoses 3 Unsupported Diagnoses = Invalid Diagnosis = Non-Medically Necessary Service 3 Providing Non-Medically Necessary Services 1. Harm to patient 2. Billing • Violation of payer contract • Violation of the False Claims Act 3 Most Common DRG Diagnoses for Hospitalization 1. Heart Failure 2. Pneumonia 3. Sepsis 4. Acute Respiratory Failure 5. Acute Kidney Injury 6. Encephalopathy 7. Chest Pain 8. Syncope/Near Syncope 3 General Principles for Physician Documentation 1. Differential Diagnoses 2. Physical exam findings for the diagnoses 3. Supported by key objective findings 4. Link the data together 5. Consistent with recognized clinical criteria 6.
    [Show full text]
  • ANAPLASMOSIS HEALTH ADVISORY Date
    To: Albany County Health Care Providers From: Ellis Tobin, M.D., Clinical Professor of Medicine, Albany Medical Center, and Upstate Infectious Diseases Associates, Albany, New York Alan Sanders, M.D., Clinical Associate Professor of Medicine, Albany Medical Center, and Upstate Infectious Diseases Associates, Albany, New York Re: ANAPLASMOSIS HEALTH ADVISORY Date: July 21, 2011 Over the past 2 months, our Infectious Diseases physician colleagues have encountered an unprecedented number of hospitalized patients with anaplasmosis (formerly known as Human Granulocytic Ehrlichiosis). Anaplasmosis is a tickborne disease transmitted by the bite of an infected Ixodes scapularis tick, commonly known as the deer tick. This is the same tick that transmits Lyme disease and babesiosis and an individual tick can be co-infected with more than one organism. We have identified more than 12 confirmed cases from 5 counties in the Capital Region admitted to area hospitals, and most of these patients have been previously evaluated by their primary care physicians, urgent care practitioners, and emergency room clinicians. These unexpected cases that have proven to be anaplasmosis could understandably be misdiagnosed as a viral syndrome or other non-specific febrile illness. There are several key clinical and laboratory characteristics that should alert clinicians to this diagnosis. All anaplasmosis-infected patients experience fever, myalgias, arthralgias, and intense fatigue. Occasional associated symptoms include mild headache, nausea, and cough. Rash and frank arthritis are absent. These symptoms tend to be mild, but on rare occasion, sepsis syndrome with multi- organ failure has occurred in untreated patients. Anaplasmosis-infected patients requiring hospitalization tend to be older than 50 years.
    [Show full text]
  • A Study on the Usefulness of Band Form Count As a Marker of Severity in Dengue Fever
    Indian Journal of Pathology and Oncology 2021;8(2):225–227 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Pathology and Oncology Journal homepage: www.ijpo.co.in Original Research Article A study on the usefulness of band form count as a marker of severity in dengue fever 1, 2 Rajeswari Kathiah *, K Kala 1Dept. of Pathology, ESIC Medical College & PGIMSR, Chennai, Tamil Nadu, India 2Dr Kamakshi Memorial Hospitals, Chennai, Tamil Nadu, India ARTICLEINFO ABSTRACT Article history: Background: Dengue fever is a mosquito borne tropical disease caused by dengue virus. Clinical features Received 29-11-2020 of dengue fever are varied and ranges from asymptomatic to life threatening shock and death. A set of Accepted 08-02-2021 investigations is used in the monitoring of the disease apart from the tests done for confirmation. No single Available online 19-05-2021 test is the gold standard in the evaluation of dengue patients that can be used as marker of clinical severity and fatality. Aim of this study is to evaluate the usefulness of band form count as a marker of severity in dengue fever. Keywords: Materials and Methods: Peripheral smears are made for all dengue cases confirmed with Dengue Immunochromatography test for NS1, IgM and IgG. The cases were categorised in to clinically stable Severe dengue dengue fever patients and severe dengue based on their clinical findings. The band form count was done by Severe dengue hemorrhagic fever manual differential count. The correlation between band form count and clinical severity was assessed. A Bandemia total of 124 cases were studied that included 23 cases of severe dengue.
    [Show full text]
  • Pulmonary Disorders, Including Vocal Cord Dysfunction
    Pulmonary disorders, including vocal cord dysfunction Paul A. Greenberger, MD, and Leslie C. Grammer, MD Chicago, Ill The lung is a very complex immunologic organ and responds in a variety of ways to inhaled antigens, organic or inorganic Abbreviations used materials, infectious or saprophytic agents, fumes, and irritants. ABPA: Allergic bronchopulmonary aspergillosis There might be airways obstruction, restriction, neither, or both ANCA: Antineutrophil cytoplasmic antibody accompanied by inflammatory destruction of the pulmonary ARDS: Acute respiratory distress syndrome BAL: Bronchoalveolar lavage interstitium, alveoli, or bronchioles. This review focuses on COPD: Chronic obstructive pulmonary disease diseases organized by their predominant immunologic CSS: Churg-Strauss syndrome responses, either innate or acquired. Pulmonary innate immune CT: Computed tomography conditions include transfusion-related acute lung injury, World FVC: Forced vital capacity Trade Center cough, and acute respiratory distress syndrome. HDAC: Histone deacetylase Adaptive immunity responses involve the systemic and mucosal LT: Leukotriene immune systems, activated lymphocytes, cytokines, and PMN: Polymorphonuclear leukocyte 1 antibodies that produce CD4 TH1 phenotypes, such as for RADS: Reactive airways dysfunction syndrome tuberculosis or acute forms of hypersensitivity pneumonitis, and TLR: Toll-like receptor 1 TRALI: Transfusion-related acute lung injury CD4 TH2 phenotypes, such as for asthma, Churg-Strauss VCD: Vocal cord dysfunction syndrome, and allergic
    [Show full text]
  • Chapter One Non-Neoplastic Disorders Of
    PART I NON-NEOPLASTIC HEMATOLOGY COPYRIGHTED MATERIAL CHAPTER ONE NON-NEOPLASTIC DISORDERS OF WHITE BLOOD CELLS Rebecca A. Levy, Vandita P. Johari, and Liron Pantanowitz OVERVIEW OF WBC PRODUCTION Leukocytes AND FUNCTION Hematopoeisis Hematopoiesis occurs in different parts of the Frequently the first test that suggests an imbalance or body, depending on the age of the embryo, child, or disturbance in hematopoiesis is the complete blood adult. Initially blood cell formation of the embryo count (CBC). The CBC is a simple blood test that occurs within the yolk sac, in blood cell aggregates is ordered frequently. It may pick up incidental called blood islands. As development progresses, abnormalities or may yield a diagnosis of suspected the hematopoiesis location changes, and the spleen abnormalities. The CBC is a count of multiple blood and liver become the primary sites. As bone marrow components and qualities, and can include a differ- develops, it usurps the task of blood cell formation ential of the white blood cells (WBCs). The CBC can and becomes the site for trilineage hematopoiesis. suggest infection, inflammatory processes, and malig- The bone marrow contains pluripotent stem cells, nant processes. Typically a peripheral blood smear which can develop into any of the blood cells, includ- and rarely a buffy coat (concentrated white blood ing granulocytes, monocytes, and lymphocytes, in cells) are analyzed to help determine a diagnosis response to specific stimulating factors (Andrews, (Efrati, 1960). A differential WBC assigns leukocytes 1994). Several white blood cells (leukocytes) are to their specific categories as a percentage or absolute depicted in Figure 1.1.
    [Show full text]
  • Clinical Vignette Competition
    2015 CLINICAL VIGNETTE Thursday, May 22 COMPETITION UTAH ACP RESIDENTS & FELLOWS COMMITTEE Scott C. Woller, MD FACP – Chair Kencee Graves, MD Julianna Desmarais, MD SPRING BANQUET & CLINICAL VIGNETTE PROGRAM FRIDAY, FEBRUARY 27, 2015 University of Utah | Guest House | Douglas Ballroom 4:45 PM WELCOME & OPENING REMARKS JUDGES Residents & Fellows Committee David Fedor, MD Josh Labrin, MD Andrea Nelson, MD 4:50 PM PRESENTATIONS An Atypical “Cold” Pg. 09 Presented by: David Gill, MD Bouncing Eyes and Tremulous Limbs Pg. 17 Presented by: Uyen T. Lam, MD Why Is This Guy’s Head Full Of Blood? Pg. 20 Presented by: Ross Smith, MD JD Congratulations, Your HgbA1c is Great! Pg. 22 Presented by: Devin West, MD 5:25 PM ANNOUNCE RUNNERS-UP AND 1ST PLACE 5:30 PM CLOSING COMMENTS – Adjourn for Dinner & Awards Ceremony Residents & Fellows Committee UTAH ACP RESIDENTS & FELLOWS COMMITTEE | MISSION STATEMENT To Improve the professional and personal lives of Utah Residents and Fellows and encourage participation in the American College of Physicians – American Society of Internal Medicine. 1. Foster Internal Medicine Resident’s interest in the ACP – ASIM. Encourage ACP associate membership and a lifelong interest in ACP – ASIM. Encourage representation on National and Local ACP subcommittees. 2. Foster educational Opportunities for Internal Medicine Residents. Encourage participation in local and national ACP – ASLIM Associates Clinical Vignette and Research opportunities. Organize the local competitions. Provide information on board review courses. Publicize local and national educational opportunities. Work with residency programs to improve residency education. 3. Identify practice management issues for Internal Medicine Residents. Provide information for residents as they prepare to enter practice, such as practice opportunities and contract negotiation.
    [Show full text]
  • Clinical Outcomes of ED Patients with Bandemia
    UC San Diego UC San Diego Previously Published Works Title Clinical outcomes of ED patients with bandemia. Permalink https://escholarship.org/uc/item/8jx2r977 Journal The American journal of emergency medicine, 33(7) ISSN 0735-6757 Authors Shi, Eileen Vilke, Gary M Coyne, Christopher J et al. Publication Date 2015-07-01 DOI 10.1016/j.ajem.2015.03.035 Peer reviewed eScholarship.org Powered by the California Digital Library University of California American Journal of Emergency Medicine 33 (2015) 876–881 Contents lists available at ScienceDirect American Journal of Emergency Medicine journal homepage: www.elsevier.com/locate/ajem Original Contribution Clinical outcomes of ED patients with bandemia Eileen Shi, B.S. a,b,⁎,GaryM.Vilke,M.D.c, Christopher J. Coyne, M.D. c, Leslie C. Oyama, M.D. c, Edward M. Castillo, PhD, MPH c a University of California San Diego Division of Biological Sciences, La Jolla, CA 92093-0935 b University of California San Diego School of Medicine, La Jolla, CA 92093-0935 c University of California San Diego School of Medicine, Department of Emergency Medicine, La Jolla, CA 92093-0935 article info abstract Article history: Background: Although an elevated white blood cell count is a widely utilized measure for evidence of infection Received 19 December 2014 and an important criterion for evaluation of systemic inflammatory response syndrome, its component band Received in revised form 13 March 2015 count occupies a more contested position within clinical emergency medicine. Recent studies indicate that Accepted 15 March 2015 bandemia is highly predictive of a serious infection, suggesting that clinicians who do not appreciate the value of band counts may delay diagnosis or overlook severe infections.
    [Show full text]
  • 2004400 October 2004, Change Report and NCD Coding Policy
    Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report October 2012 Clinical Diagnostic Laboratory Services Health & Human Services Department Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 CMS Email Point of Contact: [email protected] TDD 410.786.0727 Fu Associates, Ltd. Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. NCD Manual Changes Date Reason Release Change Edit *The following section represents NCD Manual updates for October 2012. *10/01/12 *There were no CR updates for October 2012. The following section represents NCD Manual updates for July 2012. 07/01/12 There were no CR updates for July 2012. The following section represents NCD Manual updates for April 2012. 04/01/12 ICD-9-cm code range 2012200 376.21-376.22 (190.15) Blood Counts and descriptors revised Endocrine exophthalmos 376.21-376.9 Disorders of the orbit, except 376.3 376.40-376.47 Other exophthalmic Deformity of orbit conditions (underlining in original) 376.50-376.52 Enophthalmos 376.6 Retained (old) foreign body following penetrating wound of orbit 376.81-376.82 Orbital cysts; myopathy of extraocular muscles 376.89 Other orbital disorders 376.9 Unspecified disorder of orbit The following section represents NCD Manual updates for January 2012. 01/01/12 Per CR 7621 add ICD-9- 2012100 786.50 Chest pain, (190.17) Prothrombin Time CM codes 786.50 and unspecified (PT) 786.51 to the list of ICD- 9-CM codes that are 786.51 Precordial pain covered by Medicare for the Prothrombin Time (PT) (190.17) NCD.
    [Show full text]